OBJECTIVE: Death ligand FasL, its agonistic receptor Fas, tumor necrosis factor related apoptosis inducing ligand (TRAIL) and its agonistic death receptors DR4 and DR5 are implied in carcinogenesis, tumor immune surveillance and response to chemotherapy. TRAIL receptor agonists are evaluated as anti-cancer agents. This study aimed to relate expression of death ligands/receptors and downstream initiator caspase 8 and its anti-apoptotic homologue FLICE like inhibitory protein (c-FLIP) in ovarian cancers to chemotherapy response and survival. METHODS: Fas, FasL, TRAIL, DR4, DR5, caspase 8 and c-FLIP were determined immunohistochemically on a tissue microarray containing 382 ovarian cancers. Protein expression profiles were correlated with clinicopathologic variables, chemotherapy response and survival. RESULTS: Most tumors expressed DR4, DR5, caspase 8 and c-FLIP. High c-FLIP expression was associated with expression of caspase 8 and both TRAIL receptors. TRAIL and Fas were associated with low tumor grade and better progression-free survival (HR 0.63, p=.018 and HR 0.54, p=.012), respectively, and Fas with disease-specific survival (HR 0.49, p=0.009) in univariate analysis. CONCLUSIONS: Fas and TRAIL loss is associated with dedifferentiation and worse prognosis. Expression of DR4, DR5, caspase 8 and c-FLIP by most ovarian cancers does not correlate with survival. High c-FLIP expression should be taken into account for death receptor targeted therapies.
OBJECTIVE: Death ligand FasL, its agonistic receptor Fas, tumor necrosis factor related apoptosis inducing ligand (TRAIL) and its agonistic death receptors DR4 and DR5 are implied in carcinogenesis, tumor immune surveillance and response to chemotherapy. TRAIL receptor agonists are evaluated as anti-cancer agents. This study aimed to relate expression of death ligands/receptors and downstream initiator caspase 8 and its anti-apoptotic homologue FLICE like inhibitory protein (c-FLIP) in ovarian cancers to chemotherapy response and survival. METHODS: Fas, FasL, TRAIL, DR4, DR5, caspase 8 and c-FLIP were determined immunohistochemically on a tissue microarray containing 382 ovarian cancers. Protein expression profiles were correlated with clinicopathologic variables, chemotherapy response and survival. RESULTS: Most tumors expressed DR4, DR5, caspase 8 and c-FLIP. High c-FLIP expression was associated with expression of caspase 8 and both TRAIL receptors. TRAIL and Fas were associated with low tumor grade and better progression-free survival (HR 0.63, p=.018 and HR 0.54, p=.012), respectively, and Fas with disease-specific survival (HR 0.49, p=0.009) in univariate analysis. CONCLUSIONS: Fas and TRAIL loss is associated with dedifferentiation and worse prognosis. Expression of DR4, DR5, caspase 8 and c-FLIP by most ovarian cancers does not correlate with survival. High c-FLIP expression should be taken into account for death receptor targeted therapies.
Authors: E Fountzilas; K Markou; K Vlachtsis; A Nikolaou; P Arapantoni-Dadioti; E Ntoula; G Tassopoulos; M Bobos; P Konstantinopoulos; G Fountzilas; D Spentzos Journal: Ann Oncol Date: 2012-01-04 Impact factor: 32.976
Authors: Jean-Pierre Gillet; Junbai Wang; Anna Maria Calcagno; Lisa J Green; Sudhir Varma; Mari Bunkholt Elstrand; Claes G Trope; Suresh V Ambudkar; Ben Davidson; Michael M Gottesman Journal: Mol Pharm Date: 2011-07-15 Impact factor: 4.939
Authors: Daniela Matei; Fang Fang; Changyu Shen; Jeanne Schilder; Alesha Arnold; Yan Zeng; William A Berry; Tim Huang; Kenneth P Nephew Journal: Cancer Res Date: 2012-05-01 Impact factor: 12.701
Authors: Jean-Pierre Gillet; Anna Maria Calcagno; Sudhir Varma; Ben Davidson; Mari Bunkholt Elstrand; Ram Ganapathi; Aparna A Kamat; Anil K Sood; Suresh V Ambudkar; Michael V Seiden; Bo R Rueda; Michael M Gottesman Journal: Clin Cancer Res Date: 2012-04-05 Impact factor: 12.531
Authors: Heath A Elrod; Songqing Fan; Susan Muller; Georgia Z Chen; Lin Pan; Mourad Tighiouart; Dong M Shin; Fadlo R Khuri; Shi-Yong Sun Journal: PLoS One Date: 2010-08-16 Impact factor: 3.240
Authors: E W Duiker; A Meijer; A R M van der Bilt; G J Meersma; N Kooi; A G J van der Zee; E G de Vries; S de Jong Journal: Br J Cancer Date: 2011-04-12 Impact factor: 7.640